The path to being a good investor is to be able to see what the future holds and place your bets accordingly. If you can do so often, you'll have a portfolio of winners. It's an easy game, right? There...
In recent weeks, Anixa has met with the FDA regarding their CAR-T therapy and has now scheduled a discussion around Cchek for early December. These are important events as the FDA will review data submitted before even agreeing to...
Shares in Oncocyte (OCX) are up over 200% today. This move is on the back of positive results from their liquid biopsy diagnostic for detecting lung cancer. The results from the test showed 90% sensitivity and 75% specificity, both...
Tailwinds' Take: ITUS has a potentially game-changing diagnostic here. Dr. Kumar's comments about benign studies are quite foreshadowing. We can expect to hear more about this in the future. Also note the multi-billion valuations on liquid biopsy diagnostic companies;...
On March 5th, ITUS announced an alliance with Serametrix Corporation in which the power of Cchek™ would be paired with Serametrix’s substantial expertise in immune monitoring assays. Despite the fact that shares in ITUS rallied almost 20% on this...
Tailwinds Take: with an aggressive timeline, ITUS' CAR-T therapy could be in humans in less than a year from today. If successful, it would be the first CAR-T for solid cancer, a market far bigger than any approved CAR-T...
In January we proclaimed Anixa to be Tailwinds’ stock of the year. This designation was awarded due to potential major milestones in the both the detection and the curing of cancer. With their Cchek prostate diagnostic shooting for CLIA...
Tailwinds' Take: hiring an executive to lead business development is key for Cchek as Anixa will be looking to move the product onwards towards a national diagnostic lab company sometime during 2020. SAN JOSE, Calif., Oct. 15, 2019 /PRNewswire/ -- Anixa...
Tailwinds' Take: the key takeaway from this is that the top scientists in the world are now coming on board to work with Anixa. Dr. Frazer is credited with enabling the creation of the first and only cancer vaccine...
Last month Grail Inc. raised $300 million in a Series C equity financing. This brings their total raised to around $1.5B over the last couple years. Now, I honestly don't know what valuation this last round was done at,...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.